A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines

Imhof, Laurence; Dummer, Reinhard; Dreier, Jil; Kolm, Isabel; Barysch, Marjam J

doi:10.1097/DSS.0000000000000793

Citations

Citation copied

Imhof, L., Dummer, R., Dreier, J., Kolm, I., & Barysch, M. J. (2016). A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatologic Surgery, 42(7), 853–857. https://doi.org/10.1097/DSS.0000000000000793

Abstract

BACKGROUND Quality-switched (QS) laser therapy is a safe and well-established treatment option for removing solar lentigines. Triple combination therapy (TCT) with the active pharmaceutical ingredients hydroquinone 5%, tretinoin 0.03%, and dexamethasone 0.03% is often used for skin-lightening. OBJECTIVE This prospective, open-label trial compares the efficacy and safety of a QS Ruby laser (QSRL) and a TCT in the treatment of solar lentigines. METHODS In total, 15 patients with symmetrically distributed solar lentigines on the back of